Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
OABI vs CGEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)
CGEN Overall Winner
6-Pillar Tally: OABI 1 – 5 CGEN
Matrix Metrics: OABI 4 – 6 CGEN
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over OmniAb, Inc. (OABI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OABI carries a Unified Composite Score of 56.2/100 (HOLD) at $5.05 (N/M Forward P/E, -92.9% operating margin), whereas CGEN carries 49.8/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).
- Composite vs. Pillar Nuance: While OABI currently prints a higher short-term Unified Composite Score (56.2/100 HOLD vs. CGEN 49.8/100 HOLD), CGEN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.3% vs. -92.9% operating margin) and revenue trajectory (+102.1% vs. +78.3% YoY).
- Technical & Structure Timing Caution: OABI trades in a Markup technical trend (SURGE options phase, RSI 52.6); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OABI vs CGEN
OABI
OmniAb, Inc. Common Stock
$5.05
+3.27% 1D
Market Cap
$713.3M
TTM Revenue
$40M
Forward P/E
N/M
Beta / 30D Vol
1.23β · 57% Vol
Unified Composite Score
56.2
HOLD
Tech 50.0
Fund 51.0
Flow 54.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
CGEN
Head-to-Head Winner
Compugen Ltd
$2.02
-0.98% 1D
Market Cap
$193.2M
TTM Revenue
$76M
Forward P/E
12.4x
Beta / 30D Vol
1.44β · 62% Vol
Unified Composite Score
49.8
HOLD
Tech 53.0
Fund 52.0
Flow 55.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (OABI 1 – 5 CGEN)
1. Valuation Multiples
CGEN
Forward P/E
N/M
12.4x
Trailing P/E
N/M
5.2x
PEG Ratio
N/M
1.29x
EV / Revenue
17.6x
2.5x
2. Growth & Scale
CGEN
Revenue Growth (YoY)
+78.3%
+102.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$40M
$76M
Market Cap
$713.3M
$193.2M
3. Profitability & Quality
CGEN
Gross Margin
97.7%
86.2%
Operating Margin
-92.9%
41.3%
Net Profit Margin
-108.1%
47.9%
Return on Equity (ROE)
-16.5%
57.2%
4. Balance Sheet & Cash Flow
CGEN
Cash Generation (TTM)
$2.4M
$32M EBITDA
Cash Flow Margin
5.9%
41.9% EBITDA Mgn
Net Cash / Leverage
$4.7M Net Cash
$4.3M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
OABI
Options Structure Phase
SURGE
BREAKDOWN
Current IV / %ile
125.7% (20th %ile)
89.7% (57th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
CGEN
OpEx & R&D Intensity
N/A
44.9% of Rev ($34M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OABI (4) vs CGEN (6)| Institutional Metric | OABI | CGEN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $713.3M | $193.2M | OABI | |
| Trailing P/E Ratio | N/M | 5.2x | CGEN | |
| Forward P/E Ratio | N/M | 12.4x | CGEN | |
| Revenue Growth (YoY) | +78.3% | +102.1% | CGEN | |
| Operating Margin (TTM) | -92.9% | 41.3% | CGEN | |
| Net Profit Margin | -108.1% | 47.9% | CGEN | |
| Return on Equity (ROE) | -16.5% | 57.2% | CGEN | |
| 52-Week Range Position | 90% ($1–$5) | 33% ($1–$3) | OABI | |
| Beta / 30D Volatility | 1.23β · 57% Vol | 1.44β · 62% Vol | OABI | |
| Unified Institutional Score | 56.2 / 100 (HOLD) | 49.8 / 100 (HOLD) | OABI | |
| Trailing 12M Revenue (USD) | $40M | $76M | Scale | |
| Gross Profit Margin (TTM) | 97.7% | 86.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 17.6x EV/Rev | 1.29x PEG · 2.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $2.4M ($4.7M Net Cash) | $32M EBITDA ($4.3M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
OABI +5.14 pp
3M Horizon
OABI +37.74 pp
6M Horizon
OABI +139.09 pp
1Y Horizon
OABI +200.55 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OABI Revenue | CGEN Revenue | OABI Op. Margin | CGEN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2016 | N/A | $0M | N/A | -4576.3% | CGEN |
| FY2018 | N/A | $20M | N/A | -130.5% | CGEN |
| FY2020 | N/A | $0M | N/A | -1574.8% | CGEN |
| FY2021 | $30M | $10M | -102.5% | -584.6% | OABI |
| FY2022 | $60M | $10M | -45.1% | -471.7% | OABI |
| FY2023 | $30M | $30M | -203.2% | -38.8% | CGEN |
| FY2024 | $30M | $30M | -282.3% | -53.4% | CGEN |
| FY2025 | $20M | $70M | -369.5% | 43.1% | CGEN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OABI
SURGE
Current IV
125.7%
IV Percentile
20th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact OABI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CGEN
BREAKDOWN
Current IV
89.7%
IV Percentile
57th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OABI Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CGEN Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
44.9% of Rev ($34M)
90D Engineering Disclosures
0 Published
Investor FAQ OABI vs CGEN Key Questions & Quantitative Answers
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over OmniAb, Inc. (OABI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OABI carries a Unified Composite Score of 56.2/100 (HOLD) at $5.05 (N/M Forward P/E, -92.9% operating margin), whereas CGEN carries 49.8/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Composite vs. Pillar Nuance: While OABI currently prints a higher short-term Unified Composite Score (56.2/100 HOLD vs. CGEN 49.8/100 HOLD), CGEN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.3% vs. -92.9% operating margin) and revenue trajectory (+102.1% vs. +78.3% YoY). Technical & Structure Timing Caution: OABI trades in a Markup technical trend (SURGE options phase, RSI 52.6); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CGEN leads the Growth & Scale pillar: OABI posts +78.3% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (97.7% gross margin, -92.9% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), OABI cumulative revenue shifted -33.3% while CGEN shifted +250.0%. In operating R&D and SG&A reinvestment, OABI deploys N/A (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.
CGEN screens cheaper on headline valuation multiples. OABI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.6x EV/Revenue (5.9% FCF margin), whereas CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OABI (-16.5% ROE) versus CGEN (57.2% ROE) capital efficiency.
In options market volatility and institutional positioning, OABI carries 125.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.23β · 57% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CGEN vs OABI · Reverse Pair
OABI vs OBIO
· Sector Peer
OABI vs PEPG
· Sector Peer
OABI vs DSGN
· Sector Peer
CGEN vs VCYT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma